CN116178358B - 一种靶向c-Src激酶SH3结构域的化合物及其应用 - Google Patents
一种靶向c-Src激酶SH3结构域的化合物及其应用 Download PDFInfo
- Publication number
- CN116178358B CN116178358B CN202211373648.4A CN202211373648A CN116178358B CN 116178358 B CN116178358 B CN 116178358B CN 202211373648 A CN202211373648 A CN 202211373648A CN 116178358 B CN116178358 B CN 116178358B
- Authority
- CN
- China
- Prior art keywords
- src
- protein
- cells
- activity
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 46
- 102000001332 SRC Human genes 0.000 title claims abstract description 39
- 108060006706 SRC Proteins 0.000 title claims abstract description 38
- 230000008685 targeting Effects 0.000 title claims abstract description 20
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 11
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 11
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 11
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 10
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 10
- 230000001154 acute effect Effects 0.000 claims abstract description 3
- 230000000694 effects Effects 0.000 claims description 36
- 102000000395 SH3 domains Human genes 0.000 claims description 16
- 108050008861 SH3 domains Proteins 0.000 claims description 15
- 239000003814 drug Substances 0.000 claims description 7
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000010534 mechanism of action Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 58
- 150000003384 small molecules Chemical class 0.000 abstract description 8
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 6
- 108010087686 src-Family Kinases Proteins 0.000 abstract description 6
- -1 tetrahydrobenzothiophene acetamides Chemical class 0.000 abstract description 3
- 208000004736 B-Cell Leukemia Diseases 0.000 abstract description 2
- 210000004698 lymphocyte Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 description 39
- 108090000623 proteins and genes Proteins 0.000 description 39
- 230000026731 phosphorylation Effects 0.000 description 12
- 238000006366 phosphorylation reaction Methods 0.000 description 12
- 239000012528 membrane Substances 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 238000013508 migration Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 8
- 230000003197 catalytic effect Effects 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- 108091000080 Phosphotransferase Proteins 0.000 description 7
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 7
- 125000001165 hydrophobic group Chemical group 0.000 description 7
- 230000005012 migration Effects 0.000 description 7
- 102000020233 phosphotransferase Human genes 0.000 description 7
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 7
- 230000000259 anti-tumor effect Effects 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- 102000014400 SH2 domains Human genes 0.000 description 5
- 108050003452 SH2 domains Proteins 0.000 description 5
- 208000037832 acute lymphoblastic B-cell leukemia Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000004663 cell proliferation Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102000009076 src-Family Kinases Human genes 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- 206010059866 Drug resistance Diseases 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000002033 PVDF binder Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000006180 TBST buffer Substances 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 229940041181 antineoplastic drug Drugs 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 239000008055 phosphate buffer solution Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 238000009010 Bradford assay Methods 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000009702 cancer cell proliferation Effects 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000010232 migration assay Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- STHUUBPFGZWLOV-UHFFFAOYSA-N n-[3-[(4-methylpiperidin-1-yl)-pyridin-3-ylmethyl]-4,5,6,7-tetrahydro-1-benzothiophen-2-yl]acetamide Chemical compound C1CC(C)CCN1C(C=1C=NC=CC=1)C1=C(NC(C)=O)SC2=C1CCCC2 STHUUBPFGZWLOV-UHFFFAOYSA-N 0.000 description 2
- 229910052759 nickel Inorganic materials 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000009822 protein phosphorylation Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 230000005724 C-terminal phosphorylation Effects 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 1
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000005536 L01XE08 - Nilotinib Substances 0.000 description 1
- 239000002118 L01XE12 - Vandetanib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 102000016979 Other receptors Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000052575 Proto-Oncogene Human genes 0.000 description 1
- 108700020978 Proto-Oncogene Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000008863 intramolecular interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007498 myristoylation Effects 0.000 description 1
- 229960001346 nilotinib Drugs 0.000 description 1
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229960001796 sunitinib Drugs 0.000 description 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002849 thermal shift Methods 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960000241 vandetanib Drugs 0.000 description 1
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了一种式(I)所示的四氢苯并噻吩乙酰胺类化合物以及其作为新型的靶向c‑Src蛋白SH3结构域的Src激酶小分子抑制剂的应用。本发明还公开了(I)化合物在靶向c‑Src蛋白用于预防和/或治疗人乳腺癌、宫颈癌、急性淋巴细胞B细胞白血病细胞等肿瘤疾病方面的用途。
Description
技术领域
本发明属于医药领域，涉及一种靶向c-Src蛋白SH3结构域的化合物及其应用。具体地，本发明化合物具有式(Ⅰ)所示结构。本发明公开了所述化合物作为靶向c-Src蛋白用于预防和/或治疗宫颈癌等肿瘤疾病方面的用途。本发明化合物是通过靶向SH3结构域调控c-Src激酶活性的作用机制来发挥抗肿瘤活性的，故能够克服目前临床上通过靶向c-Src激酶催化结构域发挥抗肿瘤活性的药物的易引起肿瘤细胞耐药的缺陷。
背景技术
Src蛋白酪氨酸激酶家族成员包括Src、Lyn、Fyn、Yes、Lck、Blk和Hck，其中c-Src是影响细胞增殖、分化、运动和存活等一系列信号转导通路的中枢。Src的功能调控是通过在两个位点的酪氨酸磷酸化进行的，但具有相反作用。其中，Tyr416位点的磷酸化会上调Src的催化活性，而在羧基末端尾区，在Tyr527位点的磷酸化会降低Src的催化活性。激活后的c-Src参与到正常生理和癌症发生过程包括增殖、分化、生存率和血管生成等。
SRC作为一个经典的原癌基因，编码具有酪氨酸激酶活性的c-Src蛋白。已经有多篇研究报道，c-Src在多种人类肿瘤中处于高表达状态或具有高激酶活性，并参与到癌症发生发展的多个过程中，包括细胞增殖、分化、血管生成和预后生存率等，在来自结肠、肝脏、肺、乳腺和胰腺的肿瘤中，有超过50％的c-Src激活已被证实，此外，c-Src还能促进细胞增殖、迁移、侵袭和血管生成；大量研究证实蛋白酪氨酸激酶是治疗肿瘤的重要靶点。
目前，靶向Src蛋白催化结构域的ATP竞争性抑制剂已在临床上用于肿瘤治疗。但是肿瘤细胞极易对该类药物产生耐药性，这也是目前靶向c-Src蛋白催化结构域的抗肿瘤药物面临的主要问题。c-Src蛋白由四个Src同源结构域(SH4、SH3、SH2、SH1)组成。SH4结构域定位于N末端，包含锚定上膜的豆蔻酰化序列，因此靶向Src家族激酶到质膜上。SH3结构域结合富含脯氨酸残基的氨基酸序列，籍此对c-Src活性、细胞内定位和招募c-Src底物起到重要作用。SH2结构域结合包含磷酸化酪氨酸的短模体(motif)。SH2和SH3结构域共同协作调节Src家族激酶的催化活性。SH1(催化结构域)具有激酶活性在失活的构象中，人源c-Src 527位酪氨酸被磷酸化，和它自身的SH2结构域相互作用。这种作用使得SH3结构域和富含脯氨酸的linker结构域相互作用，使c-Src维持在一个紧密结合的失活状态。一旦酪氨酸527发生去磷酸化，分子内的相互作用使c-Src处于不稳定状态导致酪氨酸416的自身磷酸化。一系列的事件使得分子打开并且释放出SH2和SH3结构域，进而和其它受体酪氨酸激酶、G蛋白偶联受体和局部黏附激酶(FAK)等发生相互作用。该蛋白在SH3结构域和多聚脯氨酸-II(PPII)螺旋之间以及SH2结构域和C端磷酸化尾巴(CTPT)之间分别含有两个自结合肽(SBP)位点，这两个位点是抗癌药物调节激酶活性的潜在靶点。
传统非受体酪氨酸激酶药物多作用于激酶催化结构域如舒尼替尼、达沙替尼、尼洛替尼、伯舒替尼、凡德他尼等，易产生耐药性，而SH3结构域作为调节Src家族激酶的催化活性的重要部分，目前尚无相关靶向该位点的抗肿瘤药物上市。
发明内容
通过蛋白热迁移实验进行高通量筛选，发现了一种新型靶向Src蛋白SH3结构域的Src激酶小分子抑制剂；并测定了其对人乳腺癌MCF-7细胞、人三阴乳腺癌MDA-MB-231细胞、宫颈癌Hela细胞、急性淋巴细胞B细胞白血病RCH-ACV细胞的抗细胞增殖活性。由此本发明的一个目的在于提供一种新型的靶向c-Src蛋白SH3结构域的Src激酶小分子抑制剂，式(Ⅰ)所示：
式(Ⅰ)所示化合物为靶向c-Src蛋白SH3结构域的抗肿瘤小分子先导化合物的发现提供了新的骨架，为设计新型靶向Src蛋白抗肿瘤药物提供了化学结构上的启示。
本发明的另一个目的在于提供式(Ⅰ)所示的化合物作为靶向Src蛋白在抗肿瘤中的用途。
式(Ⅰ)所示的化合物能够靶向c-Src蛋白SH3结构域并能有效抑制c-Src发生活化，从而抑制Src蛋白对细胞增殖、迁移、侵袭和血管生成促进活性。进而有效地预防和治疗乳腺癌、宫颈癌、急性B细胞白血病。
附图说明
图1.化合物N-{3-[(4-甲基-1-哌啶基)(3-吡啶基)甲基]-4,5,6,7-四氢-1-苯并噻吩-2-基}乙酰胺的结构式。
图2.化合物与SH3结构域蛋白热迁移实验曲线。
图3.化合物抑制宫颈癌Hela细胞活性的IC50测定曲线；图4.化合物抑制三阴乳腺癌MDA-MB-231细胞活性的IC50测定曲线；图5.化合物抑制乳腺癌细胞MCF-7活性的IC50测定曲线；图6.化合物抑制急性淋巴细胞B细胞白血病细胞RCH-ACV活性的IC50测定曲线。
图7.化合物的抗肿瘤细胞增殖活性。
图8.化合物抑制三阴乳腺癌MDA-MB-231细胞的迁移实验；图9.为通过量化图8所绘制柱状图，可明确观察出化合物81(51)对三阴乳腺癌MDA-MB-231细胞具有明显抑制迁移的能力；图10.化合物抑制宫颈癌Hela细胞的迁移实验；图11.为通过量化图10所绘制柱状图，可明确观察出化合物81(51)对宫颈癌Hela细胞具有明显抑制迁移的能力；图12.化合物抑制乳腺癌细胞MCF-7细胞的迁移实验；图13.为通过量化图12所绘制柱状图，可明确观察出化合物81(51)对乳腺癌细胞MCF-7细胞具有明显抑制迁移的能力。
图14.化合物对MDA-MB-231细胞、c-Src蛋白磷酸化作用的影响；图15.化合物对Hela细胞c-Src蛋白磷酸化作用的影响。
具体实施方式
在本发明中，采用蛋白热迁移法对候选化合物进行高通量筛选，蛋白热迁移实验是确定小分子化合物与目标蛋白是否结合的方便可靠的实验方法，广泛应用于蛋白质与小分子结合的高通量筛选中。蛋白热迁移实验的基本原理是在目标蛋白的缓冲液中加入荧光染料，使用PCR仪器将体系的温度从25℃逐步提升到80℃，在升温过程中，目标蛋白的疏水基团会从内部暴露到表面，荧光染料与暴露的疏水基团结合的程度会变高，荧光信号会增加，达到最大值后荧光会逐渐淬灭信号会下降。通过玻尔兹曼方程拟合信号曲线可求出Tm(熔解温度)值，对应为蛋白半数解链时的温度。在体系中加入小分子后，如果小分子与蛋白结合，会使蛋白的稳定性增加，即对应Tm值升高，因此，加药组与对照组相比，熔解曲线会向右迁移。
本发明中，我们通过蛋白热迁移实验发现化合物N-{3-[(4-甲基-1-哌啶基)(3-吡啶基)甲基]-4,5,6,7-四氢-1-苯并噻吩-2-基}乙酰胺与c-Src蛋白SH3结构域有结合。细胞水平的增殖抑制实验显示化合物81(51)对宫颈癌Hela细胞、三阴乳腺癌MDA-MB-231细胞、乳腺癌细胞MCF-7、急性淋巴细胞B细胞白血病细胞RCH-ACV的抗细胞增殖活性较强，且具有剂量依赖性。
本发明提供了能够靶向c-Src蛋白SH3结构域的c-Src激酶的小分子抑制剂，以及其对宫颈癌Hela细胞、三阴乳腺癌MDA-MB-231细胞、乳腺癌细胞MCF-7、急性淋巴细胞B细胞白血病细胞RCH-ACV增殖的影响。
本发明的化合物Ⅰ是通过与c-Src蛋白SH3结构域结合发挥肿瘤细胞增殖抑制活性。
下面结合具体实施例对本发明作进一步阐述，这些实施例并非限制性的，而仅作为示例说明本发明。
实施例1：蛋白质的表达和纯化。
将Src-SH3构建于Rosetta(DE3)表达载体上，载体表达的融合蛋白带有N端Trx标签和His标签，在16℃表达重组蛋白，收集菌株，超声，离心(18000rpm,30min,4℃)，取上清液。用镍亲和层析色谱(GE Healthcare)纯化蛋白质，将蛋白洗脱液收集测定浓度后，根据其浓度加入thrombin，在25℃下酶切12-16小时，次晨，以3Kd的浓缩管离心浓缩，将蛋白用蠕动泵过镍柱，穿出液即为目的蛋白。蛋白质储存在含有20mM Tris PH8.0，100mM Nacl的缓冲液中。
实施例2：蛋白热迁移实验(Protein thermal shift assay)检测小分子与蛋白的结合。
蛋白质通常以native状态存在，加热会导致蛋白质转化为Denatured状态，暴露出疏水基团。暴露出的疏水基团可以与荧光染料SYPRO Orange相结合，从而提高荧光染料的发射光，于是可以通过检测荧光强度来反映蛋白质的稳定性。不同温度下，因为蛋白质暴露疏水基团的量不同，荧光的强度也不同，于是可以画出荧光-温度曲线图。当有配体与蛋白质相结合时，蛋白质的稳定性增加，使得相同温度下暴露的疏水基团减少，需要更高的温度来使蛋白质充分暴露疏水基团。于是造成荧光-温度曲线图右移。从100mM母液制备一系列稀释浓度的待测化合物。分别加入buffer缓冲液(20mM Tris PH8.0，100mM NaCl)、c-SrcSH3蛋白、待测化合物、50×荧光染料构成20μL反应体系，为防止蛋白变性全程保持低温进行操作，使用Bio-rad荧光定量PCR，以1％升温速率，将体系温度从25℃逐渐升温至80℃，同时以20秒为间隔记录荧光强度随温度的变化情况。进一步，在Bio-Rad CFX程序中，利用Boltzmann拟合方法，计算化合物不同浓度条件下SH3的熔解温度(Tm)。
实施例3：体外细胞活性分析实验检验化合物对c-Src活性抑制引起的三阴乳腺癌细胞MDA-MB-231细胞、宫颈癌细胞Hela细胞、乳腺癌细胞MCF-7细胞、急性淋巴细胞B细胞白血病细胞RCH-ACV细胞增殖活性的影响。
在含有10％胎牛血清(FBS)和1％青霉素/链霉素的RPMI 1640培养基中，培养指数生长的细胞，以每孔2x 104个细胞的密度接种于96孔板，使用12.5μM和3.125μM的苗头化合物孵育细胞。孵育三天后，用MTT法检测细胞活性，实验结果见图3-图7。结果表明化合物81(51)对MDA-MB-231细胞、Hela细胞、MCF-7细胞、RCH-ACV表现出剂量依赖性抗增殖活性。我们的工作为发现更多的c-Src抑制剂的提供了新的骨架，并为克服目前临床上通过靶向c-Src激酶催化结构域发挥抗肿瘤活性的药物的易引起肿瘤细胞耐药的缺陷提供了新的思路。
实施例4：细胞划痕实验分析化合物对MDA-MB-231细胞、Hela细胞、MCF-7细胞迁移能力的影响。
取对数期的细胞以每孔1.5×106个细胞的密度接种入六孔板，24h后吸弃原培养基各孔分别加入无血清DMEM稀释81(51)化合物并至IC50对应浓度并设置DMSO对照孔划线后进行培养，于6h、12h、24h、36h进行观察拍照，实验数据由image J、GraphPad Prism7处理结果(图8-图13)显示81(51)对3种细胞均有明显的抑制迁移的活性，其中MDA-MB-231细胞(5-1)抑制活性最明显。
实施例5：Western Blot分析化合物对MDA-MB-231细胞c-Src蛋白Tyr416、Tyr527位磷酸化作用的影响。
取对数生长期MDA-MB-231细胞，接种于6孔板，1×106/孔，加入不同浓度DMSO稀释的81(51)化合物直终浓度分别为4μmol/L、8μmol/L、16μmol/L，帕纳替尼为阳性对照作用24小时后收集细胞，4℃预冷的PBS洗涤3次，加入75μL细胞裂解液，冰上裂解30min，提取细胞总蛋白，bradford法测蛋白质浓度。取25μg蛋白样品，10％ SDS-PAGE电泳分离蛋白后转移至PVDF膜，用5％ BSA/脱脂奶粉封闭液室温下封闭1h，洗膜后加入抗c-Src、p-c-Src(Tyr416、Tyr527)和β-actin抗体，4℃孵育过夜，TBST洗膜3次，加入二抗室温下孵育1h，TBST洗膜3次，将化学发光增强液A和B等体积混匀涂抹于PVDF膜上，用凝胶成像系统获取图像。其中Src活性通过在两个位点的酪氨酸磷酸化进行调节，但具有相反作用。在激酶结构域的活化环中，Tyr416位点的磷酸化会上调酶活性，而在羧基末端尾区，Csk在Tyr527位点的磷酸化会降低酶活性。实验结果(图14)表明在81(51)化合物24小时4μmol/L、8μmol/L、16μmol/L浓度作用下Tyr416位点的磷酸化有所下降，Tyr527位点的磷酸化有所上调均证明81(51)可抑制c-Src活性，从而抑制癌细胞增殖、迁移及侵袭活性。
实施例6：Western Blot分析化合物对Hela细胞c-Src蛋白Tyr416位磷酸化作用的影响。
取对数生长期Hela细胞，接种于6孔板，1×106/孔，加入不同浓度DMSO稀释的81(51)化合物直终浓度分别为2.15μmol/L、4.3μmol/L、8.6μmol/L，帕纳替尼为阳性对照作用24小时后收集细胞，4℃预冷的PBS洗涤3次，加入75μL细胞裂解液，冰上裂解30min，提取细胞总蛋白，bradford法测蛋白质浓度。取25μg蛋白样品，10％ SDS-PAGE电泳分离蛋白后转移至PVDF膜，用5％ BSA/脱脂奶粉封闭液室温下封闭1h，洗膜后加入抗c-Src、p-c-Src(Tyr416、Tyr527)和β-actin抗体，4℃孵育过夜，TBST洗膜3次，加入二抗室温下孵育1h，TBST洗膜3次，将化学发光增强液A和B等体积混匀涂抹于PVDF膜上，用凝胶成像系统获取图像。在激酶结构域的活化环中，Tyr416位点的磷酸化会上调酶活性。实验结果(图15)表明在81(51)化合物24小时2.15μmol/L、4.3μmol/L、8.6μmol/L浓度作用下Tyr416位点的磷酸化有所下降可证明81(51)可抑制c-Src活性，从而抑制癌细胞增殖、迁移及侵袭活性。
Claims (2)
1.包含式 I 所示化合物或其药学上可接受的盐和药学上可接受的载体的药物组合物在制备预防和/或治疗人乳腺癌、宫颈癌、急性淋巴细胞B细胞淋巴瘤的药物中的应用，其特征在于，所述式I所示化合物结构式如下：。
2.根据权利要求1所述的应用，其特征在于所述药物通过靶向SH3结构域调控c-Src激酶活性的作用机制来发挥作用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211373648.4A CN116178358B (zh) | 2022-11-04 | 2022-11-04 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211373648.4A CN116178358B (zh) | 2022-11-04 | 2022-11-04 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116178358A CN116178358A (zh) | 2023-05-30 |
| CN116178358B true CN116178358B (zh) | 2024-04-19 |
Family
ID=86442973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211373648.4A Active CN116178358B (zh) | 2022-11-04 | 2022-11-04 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116178358B (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117069657B (zh) * | 2023-08-27 | 2024-07-02 | 济南大学 | 一种靶向c-Src激酶SH3结构域的化合物及其应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101415426A (zh) * | 2006-04-07 | 2009-04-22 | 诺瓦提斯公司 | c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途 |
| NZ543959A (en) * | 2003-07-03 | 2009-08-28 | Astex Therapeutics Ltd | Benzimidazole derivatives and their use as protein kinase inhibitors |
| NZ574189A (en) * | 2006-07-07 | 2011-03-31 | Bristol Myers Squibb Co | Pyrrolotriazine kinase inhibitors |
| KR20150041751A (ko) * | 2013-10-08 | 2015-04-17 | 서울대학교산학협력단 | TM4SF5 단백질 및 c-Src 단백질의 결합억제제를 유효성분으로 포함하는 암 예방 및 치료, 또는 암 전이 억제용 조성물 |
| CN109999034A (zh) * | 2019-02-11 | 2019-07-12 | 浙江理工大学 | 肿瘤蛋白tnik激酶靶向天然小分子抑制剂及其应用 |
| CN113967210A (zh) * | 2020-07-24 | 2022-01-25 | 上海交通大学医学院附属瑞金医院 | 一种干扰整合素β3/Src相互作用的化合物的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011507910A (ja) * | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
-
2022
- 2022-11-04 CN CN202211373648.4A patent/CN116178358B/zh active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ543959A (en) * | 2003-07-03 | 2009-08-28 | Astex Therapeutics Ltd | Benzimidazole derivatives and their use as protein kinase inhibitors |
| CN101415426A (zh) * | 2006-04-07 | 2009-04-22 | 诺瓦提斯公司 | c-Src抑制剂与嘧啶基氨基苯甲酰胺类化合物的组合治疗白血病的用途 |
| NZ574189A (en) * | 2006-07-07 | 2011-03-31 | Bristol Myers Squibb Co | Pyrrolotriazine kinase inhibitors |
| KR20150041751A (ko) * | 2013-10-08 | 2015-04-17 | 서울대학교산학협력단 | TM4SF5 단백질 및 c-Src 단백질의 결합억제제를 유효성분으로 포함하는 암 예방 및 치료, 또는 암 전이 억제용 조성물 |
| CN109999034A (zh) * | 2019-02-11 | 2019-07-12 | 浙江理工大学 | 肿瘤蛋白tnik激酶靶向天然小分子抑制剂及其应用 |
| CN113967210A (zh) * | 2020-07-24 | 2022-01-25 | 上海交通大学医学院附属瑞金医院 | 一种干扰整合素β3/Src相互作用的化合物的用途 |
Non-Patent Citations (1)
| Title |
|---|
| 690640-69-8;ACS;STN registry;20040608 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116178358A (zh) | 2023-05-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sieg et al. | FAK integrates growth-factor and integrin signals to promote cell migration | |
| Mesrouze et al. | Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD | |
| Neuveut et al. | Human T-cell leukemia virus type 1 Tax and cell cycle progression: role of cyclin D-cdk and p110Rb | |
| Graeser et al. | Regulation of the CDK-related protein kinase PCTAIRE-1 and its possible role in neurite outgrowth in Neuro-2A cells | |
| Cheng et al. | Grb2 promotes integrin-induced focal adhesion kinase (FAK) autophosphorylation and directs the phosphorylation of protein tyrosine phosphatase α by the Src-FAK kinase complex | |
| US20190025332A1 (en) | MIC-1 Receptor and Uses Thereof | |
| US20110008347A1 (en) | Cancer-related protein kinases | |
| Zhao et al. | CDK inhibitor p57Kip2 is downregulated by Akt during HER2-mediated tumorigenicity | |
| Ichioka et al. | HD-PTP and Alix share some membrane-traffic related proteins that interact with their Bro1 domains or proline-rich regions | |
| Dixon-Clarke et al. | Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16 | |
| SG185832A1 (en) | Fgfr1 antibodies and treatment of cancer | |
| Zhang et al. | The substrate binding domains of human SIAH E3 ubiquitin ligases are now crystal clear | |
| Kim et al. | The integrin-coupled signaling adaptor p130Cas suppresses Smad3 function in transforming growth factor-β signaling | |
| CN116178358B (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 | |
| Emaduddin et al. | Odin (ANKS1A) is a Src family kinase target in colorectal cancer cells | |
| Li et al. | Macrophage migration inhibitory factor directly interacts with hepatopoietin and regulates the proliferation of hepatoma cell | |
| CN115716820B (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 | |
| Munier et al. | Glucocorticoid receptor Thr524 phosphorylation by MINK1 induces interactions with 14-3-3 protein regulators | |
| Nyati et al. | TGFBR2 mediated phosphorylation of BUB1 at Ser-318 is required for transforming growth factor-β signaling | |
| Coulonval et al. | Monoclonal antibodies to activated CDK4: use to investigate normal and cancerous cell cycle regulation and involvement of phosphorylations of p21 and p27 | |
| Shimizu et al. | Multimerization of the GATA4 transcription factor regulates transcriptional activity and cardiomyocyte hypertrophic response | |
| WO2019206203A1 (zh) | 调节Ras泛素化的方法 | |
| Yoodee et al. | Roles of heat-shock protein 90 and its four domains (N, LR, M and C) in calcium oxalate stone-forming processes | |
| CN117069657B (zh) | 一种靶向c-Src激酶SH3结构域的化合物及其应用 | |
| TW200539864A (en) | Oxydecahydronaphthalene modulators of HM74 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |